- BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
- BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
- BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
Key statistics
On Wednesday, Brainstorm Cell Therapeutics Inc (BCLI:NAQ) closed at 0.6002, 347.91% above the 52 week low of 0.134 set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.6597 |
---|---|
High | 0.6863 |
Low | 0.51 |
Bid | 0.5542 |
Offer | 0.5829 |
Previous close | 0.6002 |
Average volume | 1.73m |
---|---|
Shares outstanding | 48.98m |
Free float | 40.23m |
P/E (TTM) | -- |
Market cap | 29.40m USD |
EPS (TTM) | -0.4367 USD |
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼